Status:
UNKNOWN
GTA-Glyceryltriacetate for Canavan Disease
Lead Sponsor:
Sheba Medical Center
Conditions:
Infantile Canavan Disease
Deficiency Disease, Aspartoacylase
Eligibility:
All Genders
Up to 15 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether oral supplementation of glyceryl triacetate improves the clinical prognosis of Canavan Disease.
Detailed Description
Canavan Disease is caused by a deficiency in the enzyme named Aspartoacylase (ASPA). This disease is a devastating, progressive disease with no available treatment. As a result of the ASPA deficiency,...
Eligibility Criteria
Inclusion
- Age below 15 months
- Biochemically diagnosed with Canavan Disease
Exclusion
- None
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00278707
Start Date
January 1 2006
End Date
July 1 2006
Last Update
August 15 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Y. Anikster
Tel Aviv, Israel, 52621